About

About GeneQuantum Healthcare(Suzhou) Co.,Ltd GeneQuantum (GQ) is a leading ADC biotech company with proprietary one-enzyme-one-reaction bioconjugation technology and highly stable hydrophilic linkers that can generate the next generation of ADC molecules with: 1) homogeneous and site-specific conjugation for DAR2, DAR4, DAR6 and DAR8; 2) super stability with DAR value remains stable for >7 days in circulation; 3) 100% removal of ADCC without antibody engineering. We have established a highly differentiated ADC pipeline with 3 clinical stage programs, one pre-clinical program (out-licensed to Pyramid/Biohaven), and multiple programs including dual-payload ADC and radionuclide drug conjugates (RDC). Our ADC technology can be pluged & played into the current antibody manufacturing facility – no need for building dedicated ADC facilities. A number of global leading CDMOs including Wuxi XDC have licensed our technology and already completed GMP production for clinical supply. About GeneQuantum Healthcare (Suzhou) Co.,Ltd GeneQuantum (GQ) is a leading ADC biotech company with proprietary one-enzyme-one-reaction bioconjugation technology and highly stable hydrophilic linkers that can generate the next generation of ADC molecules with: 1) homogeneous and site-specific conjugation for DAR2, DAR4, DAR6 and DAR8; 2) super stability with DAR value remains stable for >7 days in circulation; 3) 100% removal of ADCC without antibody engineering. We have established a highly differentiated ADC pipeline with 3 clinical stage programs, one pre-clinical program (out-licensed to Pyramid/Biohaven), and multiple programs including dual-payload ADC and radionuclide drug conjugates (RDC). Our ADC technology can be pluged & played into the current antibody manufacturing facility – no need for building dedicated ADC facilities. A number of global leading CDMOs including Wuxi XDC have licensed our technology and already completed GMP production for clinical supply. GeneQuantum (GQ) has developed a strong pipeline of next-gen of ADCs with wider therapeutic window & higher affordability with its proprietary One-Enzyme-One-Reaction bioconjugation technology (DAR2/4/6/8, super stable both in circulation and in storage in liquid form, ADCC depletion w/o Fc engineering, ADCs manufactured in mAb facility, dual payload pADCs, RDCs, and AOCs, etc.) with 5 clinical programs including 1 currently in registration trial in China. Strategic Collaborations: Biohaven: out licensed the global right of GQ1011 (anti-FGFR3 ADC ) Biohaven: long term strategic collaboration to develop ADCs on multi-targets AimedBio: long term strategic collaboration to develop ADCs on multi-targets Pyramid: out licensed the ex-China right of GQ1010 (anti-TROP2 ADC) 2024 BD Milestone: executed 4 out-licensing deals in 2024 with total US$13B Bio$, the most # of deals done by a Chinese ADC in 2024